Loading...
BMP pathway→osteoblast differentiation→bone mineral density increase
Statins, particularly lipophilic simvastatin, promote osteoblast differentiation and mineralization through bone morphogenetic protein pathways, potentially preventing osteoporosis and reducing fracture risk. Evidence includes observational studies showing reduced osteoporosis rates and experimental mechanistic data. However, results are inconsistent and no RCT has established clinical efficacy for osteoporosis treatment.
“Simvastatin (SIM), which can treat osteoporosis by promoting osteoblast differentiation and mineralization through the bone morphogenetic proteins (BMP)-Smad signaling pathway, has lower bioavailability, and less bone tissue distribution.”
— A novel biocompatible, simvastatin-loaded, bone-targeting lipid nanocarrier for treating osteoporosis more effectively. (2020)DOI“The focus of research centers mainly on simvastatin, a lipophilic statin demonstrating efficacy in preventing osteoporosis and aiding in fracture and bone defect healing.”
— Statins-Their Role in Bone Tissue Metabolism and Local Applications with Different Carriers. (2024)DOI“Both lipophilic and hydrophilic statins were related to a decreased rate of osteoporosis in the <60-year-old female group.”
— Association between Osteoporosis and Previous Statin Use: A Nested Case-Control Study. (2021)DOI“Previous studies have revealed the protective effects of statins on bone but the association of statins use with osteoporosis-related measurement has shown controversial results.”
— Age- and dose-dependent effect of statin use on the risk of osteoporotic fracture in older adults. (2023)DOI“Other studies have further indicated that the therapeutic effect of OP in statin-treated patients is dose dependent.”
— Comparative efficacy and safety of statins for osteoporosis: a study protocol for a systematic review and network meta-analysis. (2022)DOI“(1) The results of the inverse variance weighting method showed a negative causal relationship between genetically predicted statins and osteoporosis (OR = 0.998, 95% CI 0.996-0.999, P = 0.01) risk; and a negative causal relationship between statins and osteoarthritis (OR = 0.974, 95% CI 0.951-0.998”
— The use of statins can reduce the risk of osteoarthritis and osteoporosis. (2025)DOI“Recent studies have indicated a therapeutic role of statins in decreasing the risk of osteoporosis and fractures, but conflicting results have been reported.”
— Statin use in patients with type 2 diabetes has lower risk of hip fractures: A Taiwan national population-based study. (2022)DOI“Accordingly, current knowledge encourages further clinical trials to assess the therapeutic potential of statins in the treatment of bone disorders, such as arthritis and osteoporosis.”
— The role of statins in the differentiation and function of bone cells. (2021)DOI“Overall, statins appear to have limited and site-specific effects on BMD, with insufficient evidence to support their use as a primary therapy for osteoporosis.”
— Efficacy of Statins in Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis. (2025)DOI“Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis.”
— Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis. (2022)DOI“The aim of this study was to investigate the association between the use of statins (one well-recognized cholesterol-lowering drug with anti-inflammatory properties) and the risk of osteoporosis using a drug-targeted Mendelian randomization (MR) approach.”
— Association of statin use with osteoporosis risk: a drug-targeted Mendelian randomization study. (2024)DOI“The combined use of statins and α-calcidol (α-C) for the osteoporosis prevention seems promising.”
— The Effect of Three-Month Atorvastatin and α-Calcidol Administration on Some Bone Tissue Morphometric Parameters (2021)DOI“Comparative efficacy and safety of statins for osteoporosis: A systematic review and network meta-analysis”
— Comparative efficacy and safety of statins for osteoporosis: A systematic review and network meta-analysis (2021)DOI“Bisphosphonates and denosumab are recommended for treatment of osteoporosis, and statins are used for hyperlipidemia.”
— Differential protective effects of bisphosphonates and denosumab on primary breast cancer risk, potentially to be modified by statins: a retrospective study using electronic health records (2020)DOI“Hyperlipidemia-induced osteoporosis is marked by increased bone marrow adiposity, and treatment with statins for hyperlipidemia often leads to new-onset osteoporosis.”
— AN698/40746067 suppresses bone marrow adiposity to ameliorate hyperlipidemia-induced osteoporosis through targeted inhibition of ENTR1. (2024)DOI“Osteoporosis and hyperlipidemia are closely correlated and statins might be associated with a decreased risk of fracture.”
— Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (2023)DOI